Effects of Tamoxifen Administration on the Expression of Xenobiotic Metabolizing Enzymes in Rat Liver

Cancer Research

Volumn 55, Issue 8, 1995, Pages 1780-1786

  Nuwaysir, Emile F ^a   Dragan, Yvonne P ^a   Jefcoate, Colin R ^a   Jordan, V Craig ^b   Pitot, Henry C ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; PHENOBARBITAL; TAMOXIFEN;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; DOSE RESPONSE; DRUG EFFECT; DRUG METABOLISM; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION; LIVER MICROSOME METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMAL; BASE SEQUENCE; BREAST NEOPLASMS; COMPARATIVE STUDY; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 ENZYME SYSTEM; DNA PROBES; DOSE-RESPONSE RELATIONSHIP, DRUG; EPOXIDE HYDROLASES; FEMALE; GENE EXPRESSION; HUMAN; ISOENZYMES; LIVER; MALE; MICROSOMES, LIVER; MOLECULAR SEQUENCE DATA; OXIDOREDUCTASES; RATS; RATS, INBRED F344; RNA, MESSENGER; SEX CHARACTERISTICS; STEROID HYDROXYLASES; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; XENOBIOTICS;

EID: 0028925204     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Ingle, J. N., Krook, J. E., Green, S. J., Kubista, T. P., Everson, L. K., Ahmann, D. L., Chang, M. N., Bisel, H. F., Windschitl, H. E., Twito, D. I., and Pfeifle, D. M. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J. Clin. Oncol., 4: 178–185, 1986.
2. Ward, H. W. C. Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels. Br. Med. J., 1: 13–14, 1973.
3. Fisher, B., Brown, A., Wolmark, N., et al Prolonging tamoxifen therapy for primary breast cancer. Ann. Intern. Med., 106: 649–654, 1987.
4. Jordan, V. C. Long-term tamoxifen therapy to control or to prevent breast cancer: laboratory concept to clinical trial, In: W. D. Hankins (ed.), Hormones, Cell Biology, and Cancer: Perspectives and Potentials, pp. 105–123. New York: Alan R. Liss, Inc., 1988.
5. Nayfield, S. G., Karp, J. E., Ford, L. G., Dorr, F. A., and Kramer, B. S. Potential role of tamoxifen in prevention of breast cancer. J. Natl. Cancer Inst., 83: 1450–1459, 1991.
6. lien, E. A., Solheim, E., and Ueland, P. M. Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. Cancer Res., 51: 4837–4844, 1991.
7. Lim, C. K., Yuan, Z., Lamb, J. H., White, I. N. H., De Matteis, F., and Smith, L. L. A comparative study of tamoxifen metabolism in female rat, mouse and human liver microsomes. Carcinogenesis (Lond.), 75: 589–593, 1994.
8. Robinson, S. P., Langan-Fahey, S. M., Johnson, D. A., and Jordan, V. C. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient. Drug Metab. Dispos., 19: 36–43, 1991.
9. Jacolot, F., Simon, I., Dreano, Y., Beaune, P., Riche, C., and Berthou, F. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of tamoxifen in human liver microsomes. Biochem. Pharmacol., 41: 1911–1919, 1991.
10. Mani, C., Gelboin, H. V., Park, S. S., Pearce, R., Parkinson, A., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. 1. Cytochrome P450-catalyzed iV-Demethylation and 4-hydroxylation. Drug Metab. Dispos., 21: 645–656, 1993.
11. Mani, C., Hodgson, E., and Kupfer, D. Metabolism of the antimammary cancer antiestrogenic agent tamoxifen. II. Flavin-containing monooxygenase-mediated N-oxidation. Drug Metab. Dispos., 21: 657–661, 1993.
12. Greaves, P., Goonetillek, R., Nunn, G., Topham, J., and Orton, T. Two-year carcinogenicity study in Alderley Park Wistar-derived rats. Cancer Res., 53: 3919–3924, 1993.
13. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. Major difference in the hepatocarcinogenicity and DNA adduct forming ability between toremifene and tamoxifen in female Crl:CD(BR) rats. Cancer Res., 53: 4534–4541, 1993.
14. Hirsimaki, P., Hirsimaki, Y., Nieminen, L., and Payne, B. J. Tamoxifen induces hepatocellular carcinoma in rat liver: a 1-year study with two antiestrogens. Arch. Toxicol., 67: 49–54, 1993.
15. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. V., and Kaltenberg, O. P. The triphenylethylene drug tamoxifen is a strong liver carcinogen in the rat. Carcinogenesis (Lond.), 14: 315–317, 1993.
16. Mani, C., and Kupfer, D. Cytochrome P450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res., 57: 6052–6058, 1991.
17. Han, X., and Liehr, J. G. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res., 52: 1360–1363, 1992.
18. Styles, J. A., Davies, A., Lim, C. K., De Matteis, F., Stanley, L. A., White, I. N. H., Yuan, Z-X., and Smith, L. L. Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis (Lond.), 75: 5–9, 1994.
19. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis (Lond.), 13: 2197–2203, 1992.
20. Sargent, L. M., Dragan, Y. P., Bahnub, N., Wiley, J. E., Sattler, C. A., Schroeder, P., Sattler, G. L., Jordan, V. C., and Pitot, H. C. Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res., 54: 3357–3360, 1994.
21. Pathak, D. P., and Bodell, W. J. DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis (Lond.), 75: 529–532, 1994.
22. Potter, G. A., McCague, R., and Jarman, M. A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis (Lond.), 75: 439–442, 1994.
23. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., and Poon, G. K. α-Hy-droxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res., 54: 5518–5522, 1994.
24. Phillips, D. H., Potter, G. A., Horton, M. N., Hewer, A., Crofton-Sleigh, C., Jarman, M., and Venitt, S. Reduced genotoxicity of [D5-ethyl]-tamoxifen implicates α-hy-droxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis (Lond.), 75: 1487–1492, 1994.
25. Mani, C., Pearce, R., Parkinson, A., and Kupfer, D. Involvement of cytochrome P4503A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis (Lond.), 75: 2715–2720, 1994.
26. Kawabata, T. T., Geungerich, F. P., and Baron, J. Effects of phenobarbital, trans-stilbene oxide, and 3-methylcholanthrene on epoxide hydrolase within centrilobular, midzonal, and periportal regions of rat liver. J. Biol. Chem., 256: 7767–7773 1983.
27. Thabrew, M. I., and Emerole, G. O. Variations in induction of drug-metabolizing enzymes by trans-stilbene oxide in rodent species. Biochim. Biophys. Acta, 756: 242–246, 1983.
28. Al-Turk, W. A., Stohs, S. J., and Roche, E. B. Effect of tamoxifen treatment on liver, lung and intestinal mixed-function oxidases in male and female rats. Drug Metab. Dispos., 9: 327–330, 1981.
29. Bulger, W. H., and Kupfer, D. Inhibition of the l-(o-chlorophenyl)-l-(p-chlorophe-nyl)-2,2,2-trichloroethane (o, p'DDT)- and estradiol-mediated induction of rat uterine ornithine decarboxylase by prior treatment with o, p'DDT, estradiol, and tamoxifen. Arch. Biochem. Biophys., 182: 138–146, 1977.
30. Nuwaysir, E. F., Dragan, Y. P., and Pitot, H. C. Tamoxifen induces hepatic cytochrome P450 IIB1 and IIB2 in F344 rats. The Toxicologist, 72: 917, 1992.
31. White, I. N. H., Davies, A., Smith, L. L., Dawson, S., and de Matteis, F. Induction of CYP2B1 and 3A1, and associated monooxygenase activities by tamoxifen and certain analogues in the livers of female rats and mice. Biochem. Pharmacol., 45: 21–30, 1993.
32. Ahotupa, M., Hirsimaki, P., Parssinen, R., and Mantyla, E. Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocar-cinogenesis in the rat. Carcinogenesis (Lond.), 75: 863–868, 1994.
33. Van Der Hoeven, T. A., and Coon, M. J. Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phos-phate-cytochrome P-450 reductase from rabbit liver microsomes. J. Biol. Chem., 249: 6302–6310, 1974.
34. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248–254, 1976.
35. Chomczynski, P., and N. Sacchi. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 162: 156–158, 1987.
36. Kumar, A., Raphael, C., and Adesnik, M. Cloned cytochrome P-450 cDNA. Nucleotide sequence and homology to multiple phenobarbital-induced mRNA species. J. Biol. Chem., 258: 11280–11284, 1983.
37. Gonzalez, F. J., Mackenzie, P. I., Kimura, S., and Nebert, D. W. Isolation and characterization of full-length mouse cDNA and genomic clones of 3-methylcholan-threne-inducible cytochrome P1450 and P3–450. Gene (Amst.), 29: 281–292, 1984.
38. Porter, T. D., Beck, T. W., and Kasper, C. B. Complementary DNA and amino acid sequence of rat liver microsomal, xenobiotic epoxide hydrolase. Arch. Biochem. Biophys., 248: 121–129, 1986.
39. Dunn, T. J., Koleske, A. J., Lindahl, R., and Pitot, H. C. Phenobarbital-inducible aldehyde dehydrogenase in the rat. J. Biol. Chem., 264: 13057–13065, 1989.
40. Coloma, J., and Pitot, H. C. Characterization and sequence of a cDNA clone of γ-glutamyltranspeptidase. Nucleic Acids Res., 14: 1393–1403, 1986.
41. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Laboratory, 1989.
42. Jones, C. R., and Lubet, R. A. Induction of a pleiotropic response by phenobarbital and related compounds. Responses in various inbred strains of rats, responses in various species and the induction of aldehyde dehydrogenase in Copenhagen rats. Biochem. Pharmacol., 44: 1651–1660, 1992.
43. Omiecinski, C. J., Walz, F. G., and Vlasuk, G. P. Phenobarbital induction of rat liver cytochromes P450b and P450e. J. Biol. Chem., 260: 3247–3250, 1985.
44. Diwan, B. A., Rice, J. M., Ohshima, M., Ward, J. M., and Dove, L. F. Comparative tumor-promoting activities of phenobarbital, amobarbital, barbital sodium, and barbituric acid on livers and other organs of male F344/NCr rats following initiation with N-nitrosodiethylamine. J. Natl. Cancer Inst., 74: 509–515, 1985.
45. Nims, R. W., Devor, D. E., Henneman, J. R., and Lubet, R. A. Induction of aloxyresorufin 0-dealkylase, epoxide hydrolase, and liver weight gain: correlation with liver tumor-promoting potential in a series of barbiturates. Carcinogenesis (Lond.), 8: 67–71, 1987.
46. Shinozuka, H., Lombardi, B., and Adanobi, S. E. A comparative study of the efficacy of four barbiturates as promoters of the development of y-glutamyltranspeptidase-positive foci in the liver of carcinogen treated rats. Carcinogenesis (Lond.), 3: 1017–1020, 1982.
47. Dragan, Y. P., Fahey, S., Street, K., Vaughan, J., Jordan, V. C., and Pitot, H. C. Studies of tamoxifen as a promoter of hepatocarcinogenesis in female Fischer F344 rats. Breast Cancer Res. Treat., 31: 11–25, 1994.
48. Yager, J. D., and Shi, Y. E. Synthetic estrogens and tamoxifen as promoters of hepatocarcinogenesis. Prev. Med., 20: 27–37, 1991.
49. Watnabe, M., Tanaka, H., Koizumi, H., Tanimoto, Y., Torii, R., and Yanagita, T. General toxicity studies of tamoxifen in mice and rats. Jitchuken Zenrinsko Ken-kyuko, 6: 1–36, 1980.
50. Nims, R. W., Syi, J., Wink, D. A., Nelson, V. C., Thomas, P. E., Jones, C. R., Diwan, B. A., Keefer, L. K., Rice, J. M., and Lubet, R. A. Hepatic cytochrome P450 2B-type induction by ethy/phenyl-substituted congeners of phenobarbital in the rat. Chem. Res. Toxicol., 6: 180–187, 1993.
51. Yamazoe, Y., Shimada, M., Murayama, N., and Kato, R. Suppression of levels of phenobarbital-inducible rat liver cytochrome P450 by pituitary hormone. J. Biol. Chem., 262: 7423–7428, 1987.
52. Marcus, C. B., Wilson, N. M., Jefcoate, C. R., Wilkinson, C. F., and Omiecinski, C. J. Selective induction of cytochrome P450 isozymes in rat liver by 4-n-alkyl-methyl-enedioxybenzenes. Arch. Biochem. Biophys., 277: 8–16, 1990.
53. Honkoski, P., Kojo, A., and Lang, M. A. Regulation of the mouse liver cytochrome P450 2B subfamily by sex hormones and phenobarbital. Biochem. J., 285: 979–983, 1992.
54. Tannenbaum, G. S., Gurd, W., Lapointe, M., and Pollak, M. Tamoxifen attenuates pulsatile growth hormone secretion: mediation in part by somatostatin. Endocrinology, 130: 3395–3401, 1992.
55. Malaab, S. A., Pollak, M. N., and Goodyer, C. G. Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur. J. Cancer, 28A: 788–793, 1992.
56. Alvares, A. P., Fischbein, A., Anderson, K. E., and Kappas, A. Alterations in drug metabolism in workers exposed to polychlorinated biphenyls. Clin. Pharmacol. Ther., 22: 141–146, 1977.
57. Ohnhaus, E. E., Gerber-Taras, E., and Park, B. K. Enzyme-inducing drug combinations and their effects on liver microsomal enzyme activity in man. Eur. J. Clin. Pharmacol., 24: 247–250, 1983.
58. Watkins, P. B., Wrighton, S. A., Maurel, P., Scheutz, E. G., Mendez-Picon, G., Parker, G. A., and Guzelian, P. S. Identification of an inducible form of cytochrome P-450 in human liver. Proc. Natl. Acad. Sci. USA, 82: 6310–6314, 1985.
59. Kellermann, G., and Luyten-Kellermann, M. Phenobarbital-induced drug metabolism in man. Toxicol. Appl. Pharmacol., 39: 97–104, 1977.
60. Ohnhaus, E. E., Breckenridge, A. M., and Park, B. K. Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur. J. Clin. Pharmacol., 36: 39–46, 1989.